MA
ADMS

MUFG Americas’s Adamas Pharmaceuticals ADMS Stock Holding History

MUFG Americas’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-125
Closed -$2K – 1218
2016
Q1 		$2K Buy
+125
New +$2.1K ﹤0.01% 1122

Other funds holding ADMS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BWCA
Brenner West Capital Advisors New York $804M AUM 16.19% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
CPH
C Partners Holding Zurich, Switzerland $317M AUM 4.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OTPPB
Ontario Teachers' Pension Plan Board Toronto, Ontario, Canada $3.46B AUM 7.79% 1-Year Est. Return

MUFG Americas's ADMS Position: Q2 2016 in Review

MUFG Americas sold out of Adamas Pharmaceuticals (ADMS) in Q2 2016, closing a stake of 125 shares — an estimated $2K sold.

MUFG Americas first reported a position in ADMS in Q1 2016 and held it in 1 quarter. The position peaked at $2K in Q1 2016. 84 funds tracked by Wall St. Rank hold ADMS as of Q2 2016.

  • MUFG Americas reported no remaining Adamas Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • MUFG Americas sold 125 Adamas Pharmaceuticals shares in Q2 2016, an estimated $2K.
  • MUFG Americas first reported a position in Adamas Pharmaceuticals in Q1 2016 and held it in 1 quarter.
  • MUFG Americas's Adamas Pharmaceuticals position peaked at $2K in Q1 2016.
  • 84 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q2 2016.

Based on MUFG Americas's 13F filing for Q2 2016, filed 8 Aug 2016.